Athira Pharma VP of Finance Sells Shares for $1,618 By Investing.com

Robert Renninger, vice president of finance at Athira Pharma, Inc. (NASDAQ: ATHA ), recently made several transactions in the company’s stock, according to filings with the Securities and Exchange Commission have experienced significant volatility as well InvestingPro: the data shows an 81.8% decline over the past year, although the stock is currently trading at $0.57, above a 52-week low of $0.41.The report notes sales of 2,881 shares on January 2, 2025 per share. for a weighted average price of $0.5619, which is approximately $1.618.

In addition to the sale, Renninger acquired 12,359 shares through a non-cash conversion of restricted stock units (RSUs) on December 31, 2024. Earlier, on November 18, 2024, he voluntarily disclosed that brought in 3,651 shares at $0.55 per share under the company’s Employee Stock Purchase Plan of $2,008 InvestingPro: analysis, while Athira maintains a healthy current ratio of 2.95 and has more cash than debt, the company’s overall financial health score is currently rated as WEAK.

These trades reflect Renninger’s active management of his stake in Athira Pharma, where he currently holds 89,724 shares following the recent sale.For more in-depth insight into Athira’s valuation and 11 additional key ProTips, investors can visit Pro Research comprehensive report available on the website. InvestingPro:.

In other recent news, Athira Pharma, Inc. has been notified by Nasdaq that its stock price does not meet the minimum bid price requirement and has until April 14, 2025 to regain compliance. At the same time, Athira Pharma plans to file a new registration statement with the Securities and Exchange Commission that would allow the company to offer and sell up to $300 million in securities. After the disappointing results of the AD study, which led to: Mizuho (NYSE.) Securities Downgrading Athira Pharma Shares to “Neutral” In response, Athira Pharma is shifting its focus to ATH-1105, an ALS drug currently in Phase 1 in trials, and announced a 70% workforce cut Despite the challenges, Mizuho maintained an outperform rating on Athira Pharma, while BTIG cut the stock to neutral. Finally, Athira Pharma has reached a preliminary settlement in a shareholder derivative lawsuit, reflecting its continued commitment to advancing its pipeline of therapeutic candidates.

This article is powered by AI and has been reviewed by an editor. See our T&C for more information.